Clopidogrel versus prasugrel in rabbits

Summary

The new P2Y₁₂ antagonist prasugrel produces greater inhibition of ADP-induced platelet aggregation (IPA) and reduction of thrombotic events in patients versus approved doses of clopidogrel, but increases major bleeding. We examined whether IPA level or P2Y₁₂ receptor occupancy (RO) could be optimized to better balance the efficacy and bleeding effects of these thienopyridines and reduce the response variability in rabbits. Rabbits were given three daily oral doses of clopidogrel (0.3–30 mg/ kg/d), prasugrel (0.03–10 mg/kg/d) or vehicle (n=6–40/group). Electrically-induced carotid artery thrombosis (AT, % thrombus weight reduction), cuticle bleeding time (BT, fold-increase over control), IPA to 20 μM ADP (% inhibition of peak light transmission) and RO (% inhibition of [³³P]-2MeS-ADP binding to P2Y₁-blocked platelets) were determined 2–3 hours after the last dose. ED₅₀ (doses for half-maximal effect, mg/kg/d) of AT, BT, IPA and RO were 1.6, 6.7, 1.9 and 1.4 for clopidogrel vs. 1.2, 1.9, 0.5 and 0.2 for prasugrel. IPA of 30–40% for both compounds produced the optimal balances of efficacy (AT: 50–60%) and BT of about 2-fold with significant RO of 70–80%. IPA of 50–60% achieved higher efficacy (AT: 60–80%), but with increased BT of five- to six-fold and >90% RO. Box-plot suggests no significant difference in the IPA and RO response variability between both compounds. Clopidogrel was 1.3–7 times less potent than prasugrel in rabbits, depending upon which biomarker was studied. The ratio of efficacy:bleeding was most favorable at a moderate IPA of 30% to 40%. Both compounds had similar IPA and RO response variability.

Keywords

Clopidogrel - haemostasis - platelet aggregation - prasugrel - thrombosis

• References

• 1 Savi P, Herbert J-M. Clopidogrel and ticlopidine: P2Y₁₂ adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Haemost 2005; 31: 195-204.
• 2 Mood GR, Bhatt DL. Clopidogrel and risk for acute coronary events. Curr Atheroscler Rep 2007; 09: 401-408.
• 3 Yusuf S, Zhao F, Mehta SR, Chrolavicius S. et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 4 Mehta SR, Yusuf S, Peters RJ. et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators.. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
• 5 Steinhubl SR, Berger PB, Mann JT. 3^rd, et al. CREDO Investigators.. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420.
• 6 Chen ZM, Jiang LX, Chen YP. et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group.. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 7 Sabatine MS, Cannon CP, Gibson CM. et al. CLARITY-TIMI 28 Investigators.. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
• 8 Angiolillo DJ. ADP Receptor Antagonism: What’s in the Pipeline?. Am J Cardiovasc Drugs 2007; 07: 423-432.
• 9 Wong PC, Crain EJ, Watson CA. et al. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J Cardiovasc Pharmacol 2007; 49: 316-324.
• 10 Schumacher WA, Bostwick JS, Ogletree ML. et al. Biomarker optimization to track the antithrombotic and haemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007; 322: 369-377.
• 11 Jakubowski JA, Winters KJ, Naganuma H. et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007; 25: 357-374.
• 12 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.
• 13 De Miguel A, Ibanez B, Badimón JJ. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
• 14 Sugidachi A, Asai F, Ogawa T. et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-1446.
• 15 Jarvis GE, Humphries RG, Robertson MJ. et al. ADP can induce aggregation of human platelets via both P2Y₁ and P_2T receptors. Br J Pharmacol 2000; 129: 275-282.
• 16 Gurbel PA, Bliden KP, Etherington A. et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res 2007; 121: 107-115.
• 17 Labarthe B, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol 2005; 46: 638-645.
• 18 van Werkum JW, Kleibeuker M, Mieremet N. et al. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation?. J Thromb Haemost 2007; 05: 884-886.
• 19 Packham MA, Rand ML, Kinlough-Rathbone RL. Similarities and differences between rabbit and human platelet characteristics and functions. Comp Biochem Physiol Comp Physiol 1992; 103: 35-54.
• 20 Judge HM, Buckland RJ, Sugidachi A. et al. The active metabolite of prasugrel effectively blocks the platelet P2Y₁₂ receptor and inhibits procoagulant and proinflammatory platelet responses. Platelets 2008; 19: 125-133.
• 21 Matsushima N, Jakubowski JA, Asai F. et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y₁₂ inhibitor: a multiple-dose study in healthy humans. Platelets 2006; 17: 218-226.
• 22 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators.. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.